A Double-blind, Randomised, Placebo-controlled Phase I Trial to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Topical Doses of GZ21T in Healthy Volunteers
Latest Information Update: 28 Mar 2025
At a glance
- Drugs GZ 17-6.02 (Primary)
- Indications Actinic keratosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Genzada Pharmaceuticals
- 28 Mar 2025 New trial record